Stay Up
to Date
Stay Up
to Date
Breaking News,
Updates, & More
Breaking News,
Updates, & More
Click Here to
Subscribe
Click Here to
Subscribe

In the Literature

Until recently, patients with newly diagnosed multiple myeloma who are ineligible for autologous stem-cell transplantation (ASCT), the multiagent regimen with lenalidomide (Revlimid) and dexamethasone was the standard of care. Results of the prespecified interim analysis of the MAIA trial demonstrated the benefit of adding daratumumab (Darzalex) to this combination therapy (Facon T, et al. N Engl J Med. 2019;380:2104-2115). Based on the results of this study, on July 1, 2019, the FDA approved this triple-drug regimen for use in this patient population.
Approximately 40% of patients with hormone receptor (HR)-positive, HER2-negative breast cancer have mutations in the PIK3CA gene. Although endocrine-based therapy is the standard treatment, acquired resistance remains a challenge.
The 2 chimeric antigen receptor (CAR) T-cell therapies available so far—axicabtagene ciloleucel (Yescarta) and tisagenlecleucel (Kymriah)—may be considered cost-effective treatments for adults with diffuse large B-cell lymphoma (DLBCL), depending on the long-term outcomes of these patients, according to a recent cost-effective analysis (Lin JK, et al. J Clin Oncol. 2019 Jun 3. Epub ahead of print).
Currently, there are limited therapies to prevent or delay recurrence in advanced ovarian cancer, with approximately 70% of patients having a recurrence within 3 years. The effectiveness of olaparib, an oral poly (ADP-ribose) polymerase inhibitor, in relapsed disease has been well-established; however, its benefit as a maintenance therapy in newly diagnosed advanced ovarian cancer is uncertain.
  • Venetoclax plus Rituximab Improves Outcomes in Chronic Lymphocytic Leukemia
  • Lay Navigation Reduces Medicare Costs, Resource Utilization
  • Adding Antiandrogen Therapy Improves Survival in Recurrent Prostate Cancer
  • Gaps in Use of Tyrosine Kinase Inhibitors in Medicare Beneficiaries with Chronic Myeloid Leukemia
  • Mutations Responsible for Relapse Despite PD-1 Therapy Uncovered in Melanoma
  • Ricolinostat Shows Promise in Patients with Relapsed or Refractory Multiple Myeloma
  • Inotuzumab Ozogamicin Shows Benefit in Acute Lymphoblastic Leukemia
  • Adding Daratumumab to Combination Therapy Improves Progression-Free Survival in Patients with Multiple Myeloma
  • Enzalutamide Superior to Bicalutamide in Patients with Prostate Cancer
  • Ixazomib Extends Progression-Free Survival in Multiple Myeloma
  • Pembrolizumab Shows Potential Antitumor Activity in Advanced Gastric Cancer
  • ASCO Endorses Canadian Clinical Practice Guideline on Active Surveillance for Localized Prostate Cancer
  • Delayed Relapses After Anti–PD-1 Therapy Linked to Mutation in Patients with Melanoma
  • ASCO Issues Guidelines for Developing Clinical Pathways That Promote Value-Based Care
  • Second Cancer Risk Is High After Hodgkin Lymphoma
  • Cancer Screening May Not Save Lives, a New Analysis Suggests

Results 1 - 9 of 9